Literature DB >> 17711366

VR-based conversation training program for patients with schizophrenia: a preliminary clinical trial.

Jeonghun Ku1, Kiwan Han, Hyung Rae Lee, Hee Jeong Jang, Kwang Uk Kim, Sung Hyouk Park, Jae Jin Kim, Chan Hyung Kim, In Young Kim, Sun I Kim.   

Abstract

Schizophrenia is a devastating mental illness and is characterized by hallucinations and delusions as well as social skills deficits. Generally, social skills training designed to help patients develop social skills includes role-playing, but this form of training has typical shortcomings, which are largely due to a trainer's difficulties to project emotion. Virtual reality (VR)-based techniques have the potential to solve these difficulties, because they provide a computer-generated but realistic three-dimensional world and humanlike avatars that can provide emotional stimuli. In this paper, we report on a method of implementing virtual environments (VEs) in order to train people with schizophrenia to develop conversational skills in specific situations, which could overcome the shortcomings of or complement conventional role-playing techniques. The paper reports the efficacy of the proposed approach in a preliminary clinical trial with 10 patients with schizophrenia.

Entities:  

Mesh:

Year:  2007        PMID: 17711366     DOI: 10.1089/cpb.2007.9989

Source DB:  PubMed          Journal:  Cyberpsychol Behav        ISSN: 1094-9313


  10 in total

Review 1.  The Use of Virtual Reality Technology in the Treatment of Anxiety and Other Psychiatric Disorders.

Authors:  Jessica L Maples-Keller; Brian E Bunnell; Sae-Jin Kim; Barbara O Rothbaum
Journal:  Harv Rev Psychiatry       Date:  2017 May/Jun       Impact factor: 3.732

Review 2.  Virtual reality for treatment compliance for people with serious mental illness.

Authors:  Maritta Välimäki; Heli M Hätönen; Mari E Lahti; Marjo Kurki; Anja Hottinen; Kiki Metsäranta; Tanja Riihimäki; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2014-10-08

3.  Virtual reality applications in mental health: Challenges and perspectives.

Authors:  Kalpana Srivastava; R C Das; S Chaudhury
Journal:  Ind Psychiatry J       Date:  2014 Jul-Dec

4.  RC2S: A Cognitive Remediation Program to Improve Social Cognition in Schizophrenia and Related Disorders.

Authors:  Elodie Peyroux; Nicolas Franck
Journal:  Front Hum Neurosci       Date:  2014-06-13       Impact factor: 3.169

Review 5.  Embodied Conversational Agents in Clinical Psychology: A Scoping Review.

Authors:  Simon Provoost; Ho Ming Lau; Jeroen Ruwaard; Heleen Riper
Journal:  J Med Internet Res       Date:  2017-05-09       Impact factor: 5.428

Review 6.  Perceptions and Opinions of Patients About Mental Health Chatbots: Scoping Review.

Authors:  Alaa A Abd-Alrazaq; Mohannad Alajlani; Nashva Ali; Kerstin Denecke; Bridgette M Bewick; Mowafa Househ
Journal:  J Med Internet Res       Date:  2021-01-13       Impact factor: 5.428

Review 7.  Studying and treating schizophrenia using virtual reality: a new paradigm.

Authors:  Daniel Freeman
Journal:  Schizophr Bull       Date:  2008-03-28       Impact factor: 9.306

Review 8.  A decade of research on the use of three-dimensional virtual worlds in health care: a systematic literature review.

Authors:  Reza Ghanbarzadeh; Amir Hossein Ghapanchi; Michael Blumenstein; Amir Talaei-Khoei
Journal:  J Med Internet Res       Date:  2014-02-18       Impact factor: 5.428

9.  Virtual Avatar for Emotion Recognition in Patients with Schizophrenia: A Pilot Study.

Authors:  Samuel Marcos-Pablos; Emilio González-Pablos; Carlos Martín-Lorenzo; Luis A Flores; Jaime Gómez-García-Bermejo; Eduardo Zalama
Journal:  Front Hum Neurosci       Date:  2016-08-26       Impact factor: 3.169

Review 10.  Does a Combination of Virtual Reality, Neuromodulation and Neuroimaging Provide a Comprehensive Platform for Neurorehabilitation? - A Narrative Review of the Literature.

Authors:  Wei-Peng Teo; Makii Muthalib; Sami Yamin; Ashlee M Hendy; Kelly Bramstedt; Eleftheria Kotsopoulos; Stephane Perrey; Hasan Ayaz
Journal:  Front Hum Neurosci       Date:  2016-06-24       Impact factor: 3.169

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.